cmedasНепрерывное медицинское образование и наукаContinuing Medical Education and Science2949-62923033-585XAGUcmedas-81Research ArticleОРИГИНАЛЬНЫЕ НАУЧНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHОсобенности поражения желудочно-кишечного тракта при COVID-19 (обзор актуальной литературы и собственные наблюдения)Features of gastrointestinal tract lesions in COVID-19 (review of current literature and own observations)СарсенбаеваА. С.SarsenbayevaA. S.

Сарсенбаева Айман Силкановна, доктор медицинских  наук, профессор кафедры терапии Института дополнительного профессионального образования

454092, г. Челябинск, ул. Воровского, 64; тел. +7 351 742-82-57

Chelyabinsk

aiman-ss@yandex.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSouth-Urals State Medical UniversityRussian Federation2020050820231541418Copyright © Сарсенбаева А.С., 20232023Сарсенбаева А.С.Sarsenbayeva A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cmedas.elpub.ru/jour/article/view/81

Задачи автора при написании статьи: провести систематизацию современного литературного материала о характере вовлечения желудочно-кишечного тракта в патологический процесс при COVID-19, обратить внимание врачебной аудитории на особенности курации пациентов гастроэнтерологического профиля в период пандемии.

The author's task in writing the article was to systematize the current literature on the nature of involvement of the gastrointestinal tract in the pathological process in COVID-19, to draw the attention of the medical audience to the features of the supervision of gastroenterological patients during the pandemic.

желудочно-кишечный тракткишечниквоспалительные заболевания кишечникапеченьCOVID-19bowelinflammatory bowel diseasesCOVID-19liverReferencesWang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, № 11. P. 1061–1069.Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, № 11. P. 1061–1069.Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time // Lancet Infect. Dis. 2020. Vol. 20, № 5. P. 533–534.Dong E., Du H., Gardner L. An interactive web-based dashboard to track COVID-19 in real time // Lancet Infect. Dis. 2020. Vol. 20, № 5. P. 533–534.Guan W. J., Ni Z.-Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382, № 18. P. 1708–1720.Guan W. J., Ni Z.-Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382, № 18. P. 1708–1720.Jin X., Lian J.-S., Hu J.-H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms // Gut. 2020. Vol. 69, № 6. P. 1002–1009.Jin X., Lian J.-S., Hu J.-H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms // Gut. 2020. Vol. 69, № 6. P. 1002–1009.Pan L., Mu M., Yang P. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study // Am. J. Gastroenterol. 2020. Vol. 115, № 5. P. 766–773.Pan L., Mu M., Yang P. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study // Am. J. Gastroenterol. 2020. Vol. 115, № 5. P. 766–773.Zhou P., Yang X.-L., Wang X.-G. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin // BioRxiv: The preprint server for biology. 23.01.2020. URL: https://www.biorxiv.org/content/10.1101/2020.01.22.914952v1. doi: https://doi.org/10.1101/2020.01.22.914952.Zhou P., Yang X.-L., Wang X.-G. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin // BioRxiv: The preprint server for biology. 23.01.2020. URL: https://www.biorxiv.org/content/10.1101/2020.01.22.914952v1. doi: https://doi.org/10.1101/2020.01.22.914952.Zhang H., Kang Z., Gong H. et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes // BioRxiv: The preprint server for biology. 31.01.2020. URL: https://www.biorxiv.org/content/10.1101/2020.01.30.927806v1. DOI: 10.1101/2020.01.30.927806.Zhang H., Kang Z., Gong H. et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes // BioRxiv: The preprint server for biology. 31.01.2020. URL: https://www.biorxiv.org/content/10.1101/2020.01.30.927806v1. DOI: 10.1101/2020.01.30.927806.Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS-CoV-2 // Gastroenterology. 2020. Vol. 158, № 6. P. 1831–1833.e3.Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS-CoV-2 // Gastroenterology. 2020. Vol. 158, № 6. P. 1831–1833.e3.Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor // Cell. 2020. Vol. 181, № 2. P. 271–280.e8. URL: http://www.ncbi.nlm.nih.gov/pubmed/32142651.Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor // Cell. 2020. Vol. 181, № 2. P. 271–280.e8. URL: http://www.ncbi.nlm.nih.gov/pubmed/32142651.Hung I. F. N., Cheng V. C. C., Wu A. K. L. et al. Viral loads in clinical specimens and SARS manifestations // Emerg. Infect. Dis. 2004. Vol. 10, № 9. P. 1550–1557.Hung I. F. N., Cheng V. C. C., Wu A. K. L. et al. Viral loads in clinical specimens and SARS manifestations // Emerg. Infect. Dis. 2004. Vol. 10, № 9. P. 1550–1557.Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus // Sci. Adv. 2017. Vol. 3, № 11. P. eaao4966.Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus // Sci. Adv. 2017. Vol. 3, № 11. P. eaao4966.Holshue M. L., DeBolt C., Lindquist S. et al. First case of 2019 novel coronavirus in the United States // N. Engl. J. Med. 2020. Vol. 382, № 10. P. 929–936.Holshue M. L., DeBolt C., Lindquist S. et al. First case of 2019 novel coronavirus in the United States // N. Engl. J. Med. 2020. Vol. 382, № 10. P. 929–936.Tisoncik J. R., Korth M. J., Simmons C. P. et al. Into the eye of the cytokine storm // Microbiol. Mol. Biol. Rev. 2012. Vol. 76, № 1. P. 16–32.Tisoncik J. R., Korth M. J., Simmons C. P. et al. Into the eye of the cytokine storm // Microbiol. Mol. Biol. Rev. 2012. Vol. 76, № 1. P. 16–32.Perrone F., Piccirillo M. C. Tocilizumab in COVID-19 pneumonia (TOCIVID-19): Full Text View // ClinicalTrials.gov. 12.04.2020. URL: https://clinicaltrials.gov/ct2/show/NCT04317092.Perrone F., Piccirillo M. C. Tocilizumab in COVID-19 pneumonia (TOCIVID-19): Full Text View // ClinicalTrials.gov. 12.04.2020. URL: https://clinicaltrials.gov/ct2/show/NCT04317092.Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19: Full Text View // ClinicalTrials.gov. 12.04.2020. URL: https://clinicaltrials.gov/ct2/show/NCT04315298.Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19: Full Text View // ClinicalTrials.gov. 12.04.2020. URL: https://clinicaltrials.gov/ct2/show/NCT04315298.Monteleone G., Ardizzone S. Are patients with inflammatory bowel disease at increased risk for COVID-19 infection? // J. Crohns Colitis. 2020. Vol. 14, № 9. P. 1334–1336.Monteleone G., Ardizzone S. Are patients with inflammatory bowel disease at increased risk for COVID-19 infection? // J. Crohns Colitis. 2020. Vol. 14, № 9. P. 1334–1336.Rubin D., Feuerstein J. D., Wang A. Y. et al. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary // Gastroenterology. 2020. Vol. 159, № 1. P. 350–357.Rubin D., Feuerstein J. D., Wang A. Y. et al. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary // Gastroenterology. 2020. Vol. 159, № 1. P. 350–357.Tian Y., Rong L., Nian W. et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission // Aliment. Pharmacol. Ther. 2020. Vol. 51, № 9. P. 843–851.Tian Y., Rong L., Nian W. et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission // Aliment. Pharmacol. Ther. 2020. Vol. 51, № 9. P. 843–851.Gutin L. S., Lam A. Y., Velayos F. S. et al. Going viral: management of IBD in the era of the COVID-19 pandemic // Dig. Dis. Sci. 2020. Vol. 65, № 6. P. 1571–1575.Gutin L. S., Lam A. Y., Velayos F. S. et al. Going viral: management of IBD in the era of the COVID-19 pandemic // Dig. Dis. Sci. 2020. Vol. 65, № 6. P. 1571–1575.Zhang Y., Geng X., Tan Y. et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system // Biomed. Pharmacother. 2020. Vol. 127. P. 110195.Zhang Y., Geng X., Tan Y. et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system // Biomed. Pharmacother. 2020. Vol. 127. P. 110195.Sabino-Silva R., Jardim A. C. G., Siqueira W. L. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis // Clin. Oral Investig. 2020. Vol. 24, № 4. P. 1619–1621.Sabino-Silva R., Jardim A. C. G., Siqueira W. L. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis // Clin. Oral Investig. 2020. Vol. 24, № 4. P. 1619–1621.Repici A., Maselli R., Colombo M. et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know // Gastrointest. Endosc. 2020. Vol. 92, № 1. P. 192–197.Repici A., Maselli R., Colombo M. et al. Coronavirus (COVID-19) outbreak: what the department of endoscopy should know // Gastrointest. Endosc. 2020. Vol. 92, № 1. P. 192–197.Гриневич В. Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19 // Экспериментальная и клиническая гастроэнтерология. 2020. Т. 174, № 4. С. 3–18.Гриневич В. Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19 // Экспериментальная и клиническая гастроэнтерология. 2020. Т. 174, № 4. С. 3–18.Guarner F. et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. February 2017.Guarner F. et al. World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. February 2017.Moon A. M., Webb G. J., Aloman C. et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry // J. Hepatol. 2020. Vol. 73, № 3. P. 705–708.Moon A. M., Webb G. J., Aloman C. et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry // J. Hepatol. 2020. Vol. 73, № 3. P. 705–708.Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission // Gastroenterology. 2020. Vol. 158, № 6. P. 1518–1519.Gu J., Han B., Wang J. COVID-19: gastrointestinal manifestations and potential fecal-oral transmission // Gastroenterology. 2020. Vol. 158, № 6. P. 1518–1519.Lan L., Xu D., Ye G. et al. Positive RT-PCR test results in patients recovered from COVID-19 // JAMA. 2020. Vol. 323, № 15. P. 1502–1503.Lan L., Xu D., Ye G. et al. Positive RT-PCR test results in patients recovered from COVID-19 // JAMA. 2020. Vol. 323, № 15. P. 1502–1503.

The authors declare that there are no conflicts of interest present.